Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer

@article{MadozGrpide2015ActivationOM,
  title={Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer},
  author={J. Madoz-G{\'u}rpide and S. Zazo and C. Chamizo and V. Casado and C. Caram{\'e}s and E. Gav{\'i}n and I. Crist{\'o}bal and J. Garc{\'i}a-Foncillas and F. Rojo},
  journal={Journal of Translational Medicine},
  year={2015},
  volume={13}
}
  • J. Madoz-Gúrpide, S. Zazo, +6 authors F. Rojo
  • Published 2015
  • Medicine
  • Journal of Translational Medicine
  • BackgroundActivation of the MET oncogene promotes tumor growth, invasion and metastasis in several tumor types. Additionally, MET is activated as a compensatory pathway in the presence of EGFR blockade, thus resulting in a mechanism of resistance to EGFR inhibitors.MethodsWe have investigated the impact of HGF and MET expression, MET activation (phosphorylation), MET gene status, and MET-activating mutations on cetuximab sensitivity in recurrent or metastatic squamous cell carcinoma of the head… CONTINUE READING
    Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment
    • 17
    • Highly Influenced
    • PDF
    Activated HGF-c-Met Axis in Head and Neck Cancer
    • 17
    • Highly Influenced
    • PDF

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 60 REFERENCES
    MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
    • 2,756
    • Highly Influential
    Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas
    • 301
    • Highly Influential
    • PDF
    Expression and mutational analysis of MET in human solid cancers
    • 239